Growth Metrics

Jazz Pharmaceuticals (JAZZ) Change in Receivables (2016 - 2025)

Jazz Pharmaceuticals has reported Change in Receivables over the past 16 years, most recently at $65.8 million for Q4 2025.

  • Quarterly Change in Receivables rose 7717.25% to $65.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.3 million through Dec 2025, up 403.33% year-over-year, with the annual reading at $106.3 million for FY2025, 403.33% up from the prior year.
  • Change in Receivables was $65.8 million for Q4 2025 at Jazz Pharmaceuticals, up from $51.0 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $75.5 million in Q4 2023 and troughed at -$66.0 million in Q1 2025.
  • The 5-year median for Change in Receivables is $17.4 million (2021), against an average of $18.1 million.
  • Peak annual rise in Change in Receivables hit 7717.25% in 2025, while the deepest fall reached 882.29% in 2025.
  • Tracing JAZZ's Change in Receivables over 5 years: stood at $64.8 million in 2021, then fell by 28.58% to $46.3 million in 2022, then soared by 63.11% to $75.5 million in 2023, then plummeted by 101.14% to -$864000.0 in 2024, then surged by 7717.25% to $65.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $65.8 million, $51.0 million, and $55.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.